NCT05768997 is a Phase 3 clinical trial of Ferric Derisomaltose Injection in Anemia, sponsored by Hallym University Medical Center.

Who is sponsoring NCT05768997?

NCT05768997 is sponsored by Hallym University Medical Center.

What drugs are being tested in NCT05768997?

Interventions in NCT05768997: Ferric Derisomaltose Injection, Darbepoetin Alfa Injection.

Is NCT05768997 still recruiting?

NCT05768997 is currently status unknown. Last updated 15 March 2023.

Last reviewed 2023-03-15 · How we verify

NCT05768997

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

High Dose IV Iron Plus ESA in Chemotherapy-induced Anemia

Status unknown Phase 3 Last updated 15 March 2023

What this trial tests

Phase 3 trial testing Ferric Derisomaltose Injection in Anemia in 312 participants. Status unknown.

Timeline

1 March 2023

Primary endpoint
31 December 2025

31 December 2025

Quick facts

Lead sponsor	Hallym University Medical Center
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	312
Start date	1 March 2023
Primary completion	31 December 2025
Estimated completion	31 December 2025
Sites	1 location across South Korea

Drugs / interventions tested

Ferric Derisomaltose Injection — full drug profile →
Darbepoetin Alfa Injection — full drug profile →

Conditions studied

Anemia — all drugs for Anemia →

Sponsor

Hallym University Medical Center

Who can join

19 and older, any sex, with Anemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a multicenter, prospective, randomized phase 3 clinical study comparing the efficacy and safety of the combination treatment of ESA and high-dose IV iron (darbepoietin alfa + ferric derisomaltose/iron isomaltoside) with ESA monotherapy (darbepoietin alfa alone) in CIA patients with functional iron deficiency.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Let It Grow: The Role of Growth Factors in Managing Chemotherapy-Induced Cytopenia.
Alyamany R, Alnughmush A, Alzahrani H, Alfayez M. · · 2024 · cited 2× · PMID 39727719 · DOI 10.3390/curroncol31120596

Verify or expand the search:

Other recruiting trials for Anemia

Currently open trials in the same condition.

NCT07422480 — A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myel · Phase 3 · recruiting
NCT06968936 — Long-term Outcomes Sub-Study of Preoperative Combined Iron Therapy · NA · recruiting
NCT07328191 — Quality of Life-Guided Transfusion in Refractory MDS or AML · NA · recruiting
NCT07315295 — Maximizing the Benefits of Iron in Ready-to-Use Therapeutic Foods for Malnourished Children in Kenya · NA · recruiting
NCT07400796 — Assessing Health System Readiness for Scaling Antenatal MMS in Cambodia · recruiting

Other Hallym University Medical Center trials

Trials by the same sponsor.

NCT06688565 — A Prospective, Multi-center Registry to Evaluate Safety and Efficacy of Hativ® ELectrocardiogram Monitoring on Patients · NA · unknown
NCT06175169 — IA Model for Acute Appendicitis in CT · NA · unknown
NCT05439993 — Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma · Phase 1, PHASE2 · recruiting
NCT04787354 — Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX) · Phase 3 · recruiting
NCT04192734 — Retrospective Study of Ramucirumab and Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05768997 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hallym University Medical Center
Last refreshed: 15 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05768997.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing